CLAIMS AMENDMENTS

Claim 1 (previously presented) A method of stimulating remyelination of central nervous system axons in a mammal which comprises administering to said mammal an effective amount of a monoclonal autoantibody selected from the group consisting of SCH 79.08, 01, 04, A2B5, HNK-1, antigen binding fragments thereof, monoclonal autoantibody capable of inducing remyelination of central nervous system axons and synthetic autoantibody capable of inducing remyelination of central nervous system axons.

Claim 2 (previously presented) The method of Claim 1 or 20 wherein the method of administration is intravenous administration.

Claim 3 (previously presented) The method of Claim 1 or 20 wherein the method of administration is intraperitoneal administration.

Claim 4 (previously presented) The method of Claim 1 or 20 wherein said amount of monoclonal antibody administered is between from about 0.5 mg/kg to about 400 mg/kg.

Claim 5 (canceled)

Claim 6 (canceled)

Claim 7 (canceled)

Claim 8 (canceled)

Claim 9 (previously presented) A method of treating a demyelinating disease of the central nervous system in a mammal in need of such therapy which comprises administering to said mammal an effective amount of a monoclonal autoantibody selected from the group consisting of

SCH 79.08, 01, 04, A2B5 and HNK-1, antigen binding fragments thereof, monoclonal autoantibody capable of inducing remyelination of central nervous system axons and synthetic autoantibody capable of inducing remyelination of central nervous system axons.

Claim 10 (previously presented) The method of Claim 9 or 21 wherein said mammal is a human being having multiple sclerosis, or a human or domestic animal with a viral demyelinating disease, or a post-neural disease of the central nervous system.

Claim 11 (previously presented) The method of Claim 9 or 21 wherein the method of administration is intravenous administration.

Claim 12 (previously presented) The method of Claim 9 or 21 wherein the method of administration is intraperitoneal administration.

Claim 13 (previously presented) The method of Claim 9 or 21 wherein said amount of monoclonal antibody administered is between from about 0.5 mg/kg to about 400 mg/kg.

Claim 14 (previously presented) The method of Claim 9 or 21 wherein said mammal is a mouse infected with Strain DA of Theiler's murine encephalomyelitis virus.

Claim 15 (canceled)

Claim 16 (canceled)

Claim 17 (canceled)

Claim 18 (canceled)

Claim 19 (currently amended) A pharmaceutical composition comprising as the active agent,

an ~~monoclonal~~ autoantibody comprising a synthetic autoantibody capable of inducing remyelination of central nervous system axons.

Claim 20 (previously presented) A method of stimulating remyelination of central nervous system axons in a mammal which comprises administering to said mammal an effective amount of a monoclonal autoantibody selected from the group consisting of SCH 94.03 and antigen binding fragments thereof.

Claim 21 (previously presented) A method of treating a demyelinating disease of the central nervous system in a mammal in need of such therapy which comprises administering to said mammal an effective amount of a monoclonal autoantibody selected from the group consisting of SCH 94.03 and antigen binding fragments thereof.

Claim 22 (previously presented) A pharmaceutical composition comprising as the active agent, a monoclonal antibody comprising an antigen binding fragment of SCH79.08.